Table 1 Antiretroviral Drug Use and infant feeding in the context of maternal HIV infection
Year | Mother receives | Infant receives | ||
|---|---|---|---|---|
2006 | Treatment for CD4 count < / = 200 cells/mm3 | Treatment for CD4 count > 200 cells/mm3 | ||
Lifelong ART AZT + 3TC + NVP | ARV prophylaxis starting at 28 weeks of pregnancy AZT twice daily, single dose NVP at onset of labor, AZT + 3TC during delivery and 1 week postpartum | Prophylactic ARVs for 1 week | ||
2010 | Option | Treatment for CD4 count < / = 350 cells/mm3 | Prophylaxis for CD4 count > 350 cells/mm3 | |
A | Triple ARVs starting as soon as diagnosed and continued for life | Antepartum: AZT from 14 weeks, intra-partum at onset of labor sd NVP and first dose AZT/3TC Post-partum: daily AZT/3TC through 7 days post-partum | Daily NVP from birth through 1 week beyond complete cessation of BF (if not BF or mother on treatment through ages 4–6 weeks) | |
Same initial ARVs for both | ||||
B | Triple ARVs starting as soon as diagnosed & continued for life | Triple ARVs from 14 weeks continued intra-partum and through child birth if not breastfeeding (until 1 week after cessation of BF) | Daily NVP or AZT through 4–6 weeks regardless of feeding method | |
Same for treatment and prophylaxis | ||||
B + | Triple ARVs regardless of CD4 count starting as soon as diagnosed and continued for life | Daily NVP or AZT through 4–6/52 regardless of feeding method | ||